Press Release: Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

Dow Jones
Nov 06
   --  Initial clinical data from the Phase 1 healthy-volunteer study of 
      JANX011 to be presented during an investor webcast on November 9, 2026 
 
   --  First patient dosed in the Phase 1 study evaluating JANX013 in 
      combination with JANX007 
 
   --  JANX007 Phase 1b development continues across taxane-naïve 
      monotherapy and darolutamide combination cohorts 
 
   --  JANX014 Phase 1 study continues enrolling patients with metastatic 
      castration-resistant prostate cancer (mCRPC) 
 
   --  Strong balance sheet with $945.7 million in cash, cash equivalents and 
      short-term investments supports advancement of multiple clinical-stage 
      programs 
SAN DIEGO--(BUSINESS WIRE)--November 05, 2026-- 

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended September 30, 2026, and provided a business update.

"During the third quarter, we continued to execute across our clinical portfolio, including dosing the first patient in the Phase 1 study of JANX013 in combination with JANX007," said David Campbell, Ph.D., President and Chief Executive Officer of Janux. "We are also preparing to present initial clinical data from JANX011 on November 9. JANX011 was designed to achieve deep B-cell depletion while limiting cytokine release. The upcoming clinical update will provide an initial look at how this differentiated approach translates into humans."

BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS:

Clinical and Pipeline Progress

   --  JANX007 (PSMA-TRACTr) continues to advance through Phase 1b development 
      in metastatic castration-resistant prostate cancer (mCRPC), with ongoing 
      dose optimization and expansion in taxane-naïve patients, including 
      an actively enrolling cohort evaluating JANX007 in combination with 
      darolutamide. 
 
   --  JANX014 (PSMA-TRACTr), a double-masked, PSMA-targeted tumor-activated 
      T-cell engager, continues enrollment in its Phase 1 clinical study 
      evaluating safety, pharmacokinetics and preliminary antitumor activity in 
      patients with mCRPC. 
 
   --  JANX011 (CD19-ARM) continues to be evaluated in a Phase 1 clinical 
      study in healthy volunteers. JANX011 is Janux's first clinical candidate 
      from its Adaptive Immune Response Modulator (ARM) platform and was 
      designed to achieve deep and durable B-cell depletion while limiting 
      cytokine release. Initial clinical data from the study will be presented 
      during an investor webcast on November 9, 2026. 
 
          --  Janux recently disclosed that JANX011 selectively engages 
             TRBV6-expressing T cells rather than broadly engaging the CD3+ T 
             cell population, a differentiated approach intended to focus 
             immune activation on a defined T cell subset. 
 
 
 
   --  JANX013 (PSMA-TRACIr) The first patient has been dosed in the Phase 1 
      study evaluating JANX013 in combination with JANX007 in patients with 
      mCRPC, representing the first clinical evaluation of Janux's TRACIr 
      platform. 

Upcoming Milestones

   --  Initial clinical data from the Phase 1 healthy-volunteer study of 
      JANX011 will be presented during an investor webcast, providing the first 
      clinical evaluation of Janux's ARM platform. 
 
   --  Additional clinical data from the Phase 1b study of JANX007 are 
      expected to be presented at a medical congress in the first half of 
      2027. 

THIRD QUARTER 2026 FINANCIAL RESULTS:

   --  Cash and cash equivalents and short-term investments: As of September 
      30, 2026, Janux reported cash and cash equivalents and short-term 
      investments of $945.7 million, compared to $966.6 million as of December 
      31, 2025. 
 
   --  Research and development expenses: Research and development expenses 
      were $30.6 million for the quarter ended September 30, 2026, compared to 
      $34.6 million for the comparable period in 2025. 
 
   --  General and administrative expenses: General and administrative 
      expenses were $10.0 million for the quarter ended September 30, 2026, 
      compared to $10.6 million for the comparable period in 2025. 
 
   --  Net loss: Net loss was $21.6 million for the quarter ended September 
      30, 2026, compared to $24.3 million for the comparable period in 2025. 

About Janux Therapeutics

Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms.

Janux's lead clinical candidate, JANX007, is a PSMA-targeted TRACTr being investigated in a Phase 1 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also advancing additional PSMA-targeted programs, including JANX014, a double-masked PSMA-TRACTr being evaluated in a Phase 1 clinical trial, and JANX013, a CD28 co-stimulatory TRACIr designed for combination with JANX007 and being evaluated in a Phase 1 clinical trial.

Beyond its prostate cancer programs, Janux's pipeline includes JANX011, a CD19-targeted ARM being evaluated in a Phase 1 clinical trial in healthy adult volunteers for potential treatment of autoimmune diseases.

Janux continues to generate additional TRACTr, TRACIr, and ARM programs for potential future development.

For more information, please visit www.januxrx.com and follow us on LinkedIn.

Forward-Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux's ability to bring new treatments to patients in need, expectations regarding the timing, scope and results of Janux's development activities, including its ongoing and planned preclinical studies and clinical trials, and the potential benefits of Janux's product candidates and platform technologies, expectations regarding the use of Janux's platform technologies to generate novel product candidates and the strength of Janux's balance sheet and the adequacy of cash on hand. Factors that may cause actual results to differ materially include the risk that interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations, the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may, " "will," "would," "could," "should," "believes," "estimates," "projects, " "promise," "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

 
                        Janux Therapeutics, Inc. 
                        Condensed Balance Sheets 
                             (in thousands) 
 
                                        September 30,    December 31, 
                                             2026            2025 
                                       ---------------  -------------- 
Assets                                   (unaudited) 
Current assets: 
   Cash and cash equivalents           $        41,818  $       52,334 
   Accounts receivable, net                        411              -- 
   Short-term investments                      903,899         914,233 
   Prepaid expenses and other current 
    assets                                      13,254           9,320 
                                           -----------      ---------- 
Total current assets                           959,382         975,887 
Restricted cash                                    816             816 
Property and equipment, net                      2,795           3,852 
Operating lease right-of-use assets             16,772          18,402 
Other long-term assets                           3,890           2,608 
                                           -----------      ---------- 
Total assets                           $       983,655  $    1,001,565 
                                           ===========      ========== 
 
Liabilities and Stockholders' Equity 
Current liabilities: 
   Accounts payable                    $         4,303  $        4,971 
   Accrued expenses                             20,089          17,633 
   Current portion of deferred 
   revenue                                      27,221              -- 
   Current portion of operating lease 
    liabilities                                  2,634           2,393 
                                           -----------      ---------- 
Total current liabilities                       54,247          24,997 
Deferred revenue, net of current 
portion                                             50              -- 
Operating lease liabilities, net of 
 current portion                                17,746          19,746 
                                           -----------      ---------- 
Total liabilities                               72,043          44,743 
Total stockholders' equity                     911,612         956,822 
                                           -----------      ---------- 
Total liabilities and stockholders' 
 equity                                $       983,655  $    1,001,565 
                                           ===========      ========== 
 
 
                            Janux Therapeutics, Inc. 
       Unaudited Condensed Statements of Operations and Comprehensive Loss 
                 (in thousands, except share and per share data) 
 
                            Three Months Ended           Nine Months Ended 
                               September 30,               September 30, 
                         -------------------------   ------------------------- 
                            2026          2025          2026          2025 
                         -----------   -----------   -----------   ----------- 
Collaboration revenue    $     9,289   $    10,000   $    23,289   $    10,000 
Operating expenses: 
   Research and 
    development               30,565        34,629        88,372        94,348 
   General and 
    administrative             9,982        10,622        32,078        30,918 
                          ----------    ----------    ----------    ---------- 
Total operating 
 expenses                     40,547        45,251       120,450       125,266 
                          ----------    ----------    ----------    ---------- 
Loss from operations         (31,258)      (35,251)      (97,161)     (115,266) 
Total other income             9,688        10,938        29,258        33,587 
                          ----------    ----------    ----------    ---------- 
Net loss                 $   (21,570)  $   (24,313)  $   (67,903)  $   (81,679) 
                          ==========    ==========    ==========    ========== 
Other comprehensive 
gain (loss): 
   Unrealized gain 
    (loss) on 
    available-for-sale 
    securities, net           (4,189)          815       (10,810)        2,399 
                          ----------    ----------    ----------    ---------- 
Comprehensive loss       $   (25,759)  $   (23,498)  $   (78,713)  $   (79,280) 
                          ==========    ==========    ==========    ========== 
Net loss per common 
 share, basic and 
 diluted                 $     (0.34)  $     (0.39)  $     (1.08)  $     (1.32) 
                          ==========    ==========    ==========    ========== 
Weighted-average shares 
 of common stock 
 outstanding, basic and 
 diluted                  63,089,950    62,023,685    62,899,208    61,906,789 
                          ==========    ==========    ==========    ========== 
 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261105303093/en/

 
    CONTACT:    Investors: 

Chad Rubin

Endurance Advisors

crubin@enduranceadvisors.com

646.319.3261

Media:

Jessica Yingling, Ph.D.

Little Dog Communications Inc.

jessica@litldog.com

858.344.8091

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10